[A combined radiochemotherapy trial for non-small cell lung cancers: initial results]

Cancer Radiother. 1997;1(2):170-3. doi: 10.1016/s1278-3218(97)83536-6.
[Article in French]

Abstract

Purpose: Analysis of the preliminary results of a phase I study investigating the feasibility of concomitant chemotherapy with daily doses of carboplatin (20 to 25 mg/m2/d over 45 or 10 min) and accelerated chest irradiation (60 to 64 Gy over 4 weeks, 2 Gy per fraction, using the concomitant boost technique).

Materials and methods: This combination was given alone or following three cycles of induction chemotherapy (cisplatin, 25 mg/m2 per day from d1 to d5; 5-fluorouracil, 600 mg/m2 per day from d1 to d5 and vinorelbine, 25 mg/m2 per day at d1 and d5 with a 4-week interval) in 15 patients with locally advanced unresectable non-small cell lung cancer. All patients received the planned sequence.

Results: The dose-limiting toxicity was esophagitis (5 out of 15 grade 4). No toxic deaths were observed. The tumor response rate was high: six out of 15 complete responses and 14 out of 15 tumor regressions greater than 50%. The median survival was not reached after a mean follow-up of 14 months (range, 6-28 months).

Conclusion: We are now planning a multicenter phase II study using the following combination: 20 mg/m2 of daily carboplatin over 10 min and a 60-Gy irradiation dose over 4 weeks.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • English Abstract
  • Randomized Controlled Trial

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Carboplatin / therapeutic use*
  • Carcinoma, Bronchogenic / drug therapy*
  • Carcinoma, Bronchogenic / mortality
  • Carcinoma, Bronchogenic / pathology
  • Carcinoma, Bronchogenic / radiotherapy*
  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / radiotherapy*
  • Chemotherapy, Adjuvant
  • Combined Modality Therapy
  • Drug Administration Schedule
  • Feasibility Studies
  • Female
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Lung Neoplasms / radiotherapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Radiotherapy Dosage
  • Survival Analysis
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Carboplatin